References
- InadaTEvaluation and diagnosis of drug-induced extrapyramidal symptomsYagiGCommentary on the DIEPSS and Guide to Its UsageToykoSeiwa Publishers19961160
- HamiltonMDevelopment of a rating scale for primary depressive illnessBr J Soc Clin Psychol1967642782966080235
- de RondeMWKingmaHJMuntsAGSevere Parkinsonism due to metoclopramide: the importance of early recognitionNed Tijdschr Geneeskd201315726A6037 Dutch23835236
- OyewoleAOAdelufosiAOAbayomiOAcute dystonic reaction as medical emergency: a report of two casesAnn Med Health Sci Res20133345345524116333
- MoosDDHansenDJMetoclopramide and extrapyramidal symptoms: a case reportJ Perianesth Nurs200823529229918926476
- NicholsonSDExtra pyramidal side effects associated with paroxetineWest Engl Med J1992107390911308691
- LeoRJMovement disorders associated with the serotonin selective reuptake inhibitorsJ Clin Psychiatry199657104494548909330
- SchillevoortIvan PuijenbroekEPde BoerARoosRAJansenPALeufkensHGExtrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reportsInt Clin Psychopharmacol2002172757911892721
- DestaZWUGMMorochoAMFlockhartDAThe gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6Drug Metab Dispos200230333634311854155